Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Daxor Corp DXR

Healthcare Medical Devices

Daxor Corporation is a blood volume measurement technology company, which is focused on blood volume testing innovation. The Company has developed and marketed the Blood Volume Analyzer (BVA-100), the diagnostic blood test cleared by the food and drug administration (FDA) to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific... see more

Add To Watchlist

Recent & Breaking News (NDAQ:DXR)

Daxor Corporation Awarded $305K Grant from the National Institutes of Health to Develop Blood Volume Guidance Software in Sepsis Patients

GlobeNewswire September 11, 2023

Daxor Corporation to Present at the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 7, 2023

Daxor Corporation CEO and President Michael Feldschuh Provides Corporate Update in Letter to Shareholders

GlobeNewswire August 28, 2023

Daxor Corporation Reports a 20.64 Percent Increase in Diagnostic Test Kits Revenue From Prior Year Period in Form N-CSR Filing for the Six Months Ended June 30, 2023

GlobeNewswire August 28, 2023

JACC-HF Reports Successful Heart Failure Trial With Daxor BVA-100®

GlobeNewswire August 10, 2023

JACC-HF Study Compares Daxor's BVA-100® Volume Metric to CardioMEMS® Pressure Metric in Heart Failure Patients

GlobeNewswire July 12, 2023

Daxor Corporation Announces Further Acquisitions and Increased Utilization of its BVA-100® Blood Volume Diagnostic Throughout the U.S.

GlobeNewswire July 11, 2023

Daxor Corporation Awarded $1.1 Million Contract from the United States Defense Health Agency for Added Capabilities to its Point-of-Care Blood Volume Analyzer

GlobeNewswire July 5, 2023

Daxor Corporation Announces Partial Exercise of Over-Allotment Option in Secondary Offering

GlobeNewswire June 22, 2023

Daxor Corporation to Showcase the Benefits of BVA-100® Guided Care at the American Association of Heart Failure Nurses (AAHFN) 19th Annual Meeting

GlobeNewswire June 20, 2023

Daxor Accelerates Blood Volume Analysis Adoption with the Launch of ezBVA Lab Services

GlobeNewswire June 15, 2023

Daxor Corporation to Participate in the Maxim Group Virtual Healthcare Conference

GlobeNewswire June 12, 2023

Daxor Corporation Announces Closing of $4.0 Million Underwritten Public Offering

GlobeNewswire May 25, 2023

Daxor Corporation Announces Pricing of $4.0 Million Underwritten Public Offering

GlobeNewswire May 22, 2023

Daxor Corporation Announces Proposed Underwritten Public Offering

GlobeNewswire May 19, 2023

New Study Demonstrates Clinical Utility of Daxor's Blood Volume (BVA-100®) Diagnostic in Heart Failure Outcomes

GlobeNewswire May 18, 2023

New Studies Presented at the 43rd International Society for Heart and Lung Transplant Validate the Applicability of the BVA-100® Blood Test for Patients with Advanced Heart Failure

GlobeNewswire April 20, 2023

Daxor Corporation to Exhibit at the MedAxiom Cardiovascular Transforum Conference Spring'23 to Advance Awareness and Further Adoption of Daxor's Blood Volume Diagnostic (BVA-100®)

GlobeNewswire April 17, 2023

Daxor Corporation to Exhibit at the 43rd International Society for Heart and Lung Transplant (ISHLT) Annual Meeting and Scientific Sessions

GlobeNewswire April 13, 2023

Daxor Corporation Announces Significant Expansion With Five Hospitals Implementing Its BVA-100® Blood Volume Diagnostic for Heart Failure Patients

GlobeNewswire March 27, 2023